SCHEMBL4357630

SCHEMBL4357630

COc1cc(C2=NC(c3cc[nH]n3)=C3C=NC=C[N+]23N)ccc1Oc1ccccc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 1/20 0.34
IGF1R P08069 1/20 0.34
FGFR1 P11362 1/20 0.34
NTRK2 Q16620 1/20 0.34
TTR P02766 3/20 0.33
TNK2 Q07912 3/20 0.33
FYN P06241 1/20 0.31
ACHE P22303 1/20 0.31
BTK Q06187 1/20 0.31
AGTR1 P30556 1/20 0.30
KDM4E B2RXH2 1/20 0.30
MEN1 O00255 1/20 0.30
USP2 O75604 1/20 0.30
ALDH1A1 P00352 1/20 0.30
HPGD P15428 1/20 0.30
TSHR P16473 1/20 0.30
MAPK1 P28482 1/20 0.30
HTT P42858 1/20 0.30
KMT2A Q03164 1/20 0.30
ATM Q13315 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1129124 0.85 XDH (0.33) BTK
SCHEMBL4361647 0.85 TTR (0.36) NTRK1IGF1RFGFR1NTRK2TTR
SCHEMBL4356460 0.84 TNK2 (0.34) NTRK1IGF1RFGFR1NTRK2TNK2
SCHEMBL4362619 0.77 AR (0.38) TNK2KDM4EALDH1A1TSHRMAPK1
SCHEMBL4366693 0.76 TNK2 (0.36) TNK2
SCHEMBL4352499 0.76 AR (0.35) TNK2
SCHEMBL4357710 0.76 ALDH1A1 (0.37) ALDH1A1MAPK1HTT
SCHEMBL4364558 0.75 TNK2 (0.34) TNK2MEN1ALDH1A1TSHRKMT2A
SCHEMBL1128963 0.75 TNK2 (0.34) TNK2
SCHEMBL4354319 0.75 NTRK1 (0.32) NTRK1IGF1RFGFR1NTRK2TNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8481733-B2 Substituted imidazopyr- and imidazotri-azines OSI Pharmaceuticals, LLC (US) 2013-07-09 US claimed
EP-2283020-B1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI PHARM INC (US) 2012-10-31 EP claimed
US-8481733-B2 Substituted imidazopyr- and imidazotri-azines OSI Pharmaceuticals, LLC (US) 2013-07-09 US disclosed
EP-2283020-B1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI PHARM INC (US) 2012-10-31 EP disclosed
US-20090286768-A1 SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES OSI PHARMACEUTICALS, INC. (US) 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286768-A1 SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES ABL1, TPMT, CYP2C19 NTRK1 2072/4885IGF1R 138/4885FGFR1 163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.